Ilorasertib hydrochloride (Synonyms: ABT-348 hydrochloride) |
| Catalog No.GC38519 |
Le chlorhydrate d'ilorasertib (ABT-348) est un inhibiteur d'aurore puissant, actif par voie orale et compétitif pour l'ATP avec des CI50 de 116, 5, 1 nM pour l'aurore A, l'aurore B, l'aurore C, respectivement. Le chlorhydrate d'ilorasertib est également un puissant inhibiteur du VEGF et du PDGF. Le chlorhydrate d'ilorasertib a le potentiel pour la recherche sur la leucémie myéloÏde aiguë (LMA) et le syndrome myélodysplasique (SMD).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1847485-91-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ilorasertib hydrochloride (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A with IC50s of 1 nM, 7 nM, 120 nM, respectively. Ilorasertib hydrochloride (ABT-348 hydrochloride) also suppresses RET tyrosine kinase, PDGFRβ and Flt1 with IC50s of 7 nM, 3 nM and 32 nM, respectively[1].
[1]. Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *